Update
$Immutep(IMMP.US$ Immutep Signs Agreement With Cardiff University for Development Cancer Treatment
MT Newswires· 7 mins ago
Biotechnology company Immutep (ASX:IMM) entered into an exclusive agreement with Cardiff University for the development and commercialization of anti-LAG-3 small molecules for cancer treatment, according to a Tuesday filing with the Australian Securities Exchange.
A milestone payment of 25,000 pounds sterling will be given to University College Cardiff Consultants, an affiliate of Cardiff University, upon the first commercial sale of a licensed product, the filing said. University College Cardiff Consultants will be eligible to receive low single-digit sales-based royalties under the terms of the agreement.
Immutep S.A.S. and University College Cardiff Consultants submitted a joint patent application, per the filing, to safeguard the new intellectual property.
MT Newswires· 7 mins ago
Biotechnology company Immutep (ASX:IMM) entered into an exclusive agreement with Cardiff University for the development and commercialization of anti-LAG-3 small molecules for cancer treatment, according to a Tuesday filing with the Australian Securities Exchange.
A milestone payment of 25,000 pounds sterling will be given to University College Cardiff Consultants, an affiliate of Cardiff University, upon the first commercial sale of a licensed product, the filing said. University College Cardiff Consultants will be eligible to receive low single-digit sales-based royalties under the terms of the agreement.
Immutep S.A.S. and University College Cardiff Consultants submitted a joint patent application, per the filing, to safeguard the new intellectual property.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
F HALE : They are doing great work in curing this terrible disease